MedInTech is a South Korea-based medical smart endoscope developer focused on AI-enabled diagnosis. The company was founded in 2020 and is led by CEO Chiwon Lee. It raised a KRW 20 billion Series B round in May 2024.
Access to pre-IPO shares is available to accredited investors through UpMarket.
MedInTech shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Full offering memoranda and risk disclosures provided before any commitment is required.
Review and sign subscription agreement. All documents handled digitally through the platform.
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
EY says global MedTech annual revenue reached nearly US$600 billion in the latest outlook, with commercial leaders tracking 6%-7% revenue growth. McKinsey also says 25% of the medtech market is projected to grow at 6% or more a year from 2022 to 2025.
Healthcare Digital says top 2026 Series C healthtech companies show a clear compliance moat through early alignment with the EU AI Act and MDR/IVDR. The same source cites Rule of 40 above 60% and LTV:CAC above 4:1 as signs of capital-efficient scale.
Bessemer Venture Partners says the most direct ROI measure for healthcare SaaS is incremental revenue, or the extra revenue a customer expects from the product. The firm also recommends defining ROI upfront and tracking it over time to prove value.
Interested in MedInTech stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
Request access →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, MedInTech is a private company and does not trade on any public stock exchange. Accredited investors can access MedInTech shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
MedInTech does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in MedInTech shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.
Pre-IPO investments carry significant risks. MedInTech shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
MedInTech develops AI-enabled smart endoscopes, generated under $5M in 2024 revenue, and is positioned to benefit as the medtech market nears $600B while growth remains in the mid-single digits — accredited investors can access MedInTech stock through UpMarket.